Mumps pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Changes made per Mahshid's request)
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
<div style="-webkit-user-select: none;">
{|class="infobox" style="position: fixed; top: 65%; right: 10px; margin: 0 0 0 0; border: 0; float: right;
|-
| {{#ev:youtube|https://https://www.youtube.com/watch?v=s3ACcn8IWFc|350}}
|-
|}
__NOTOC__
__NOTOC__
{{Mumps}}
{{Mumps}}
Line 38: Line 44:


[[Category:Disease]]
[[Category:Disease]]
[[Category:Infectious disease]]
 
[[Category:Pediatrics]]
[[Category:Pediatrics]]
[[Category:Dermatology]]
[[Category:Dermatology]]

Latest revision as of 18:07, 18 September 2017

https://https://www.youtube.com/watch?v=s3ACcn8IWFc%7C350}}

Mumps Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Mumps from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mumps pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mumps pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mumps pathophysiology

CDC on Mumps pathophysiology

Mumps pathophysiology in the news

Blogs on Mumps pathophysiology

Directions to Hospitals Treating Mumps

Risk calculators and risk factors for Mumps pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2]; Nate Michalak, B.A.

Overview

Humans are the only natural host for mumps virus (MuV). MuV is transmitted through respiratory droplets (saliva or mucus), direct contact, or contact with surfaces carrying MuV. MuV infects the upper respiratory tract epithelium by binding to extracellular sialic acid via the hemagglutinin-neuraminidase (HN) glycoprotein. MuV is able to evade an immune response with small hydrophobic (SH) protein, which blocks TNFα-mediated apoptosis, and with the V proteins, which inhibit IFN production and signaling. MuV disseminates through the lymphatic system to cause systemic infection. Replication in the parotid gland (or other salivary gland) causes mononuclear cell infiltration, hemorrhage, edema, and necrosis.

Pathophysiology

Transmission

  • Humans are the only natural host for mumps virus (MuV).
  • MuV is transmitted through respiratory droplets (saliva or mucus), direct contact, or contact with surfaces carrying MuV.
  • Mumps is contagious several days prior and up to 5 days after onset of parotitis.

Pathogenesis

  • MuV enters the body through inhalation or oral contact and infects the upper respiratory tract epithelium.[1]
  • MuV is able to attach to extracellular sialic acid via the hemagglutinin-neuraminidase (HN) glycoprotein.
  • HN and the fusion (F) glycoprotein mediate cell membrane fusion, allowing viral material to enter respiratory epithelial cells.
  • HN and F, in conjunction with matrix (M) protein, are also involved in localizing viral material after replication and inducing virion budding.
  • MuV is able to inhibit an immune response to infection with the following virulence factors:
  • Small hydrophobic (SH) protein is presumed to block TNFα-mediated apoptosis.[2]
  • Non-structural proteins NS1 and NS2 (V proteins) inhibit IFN production and signaling.[3]

Virulence Factors

  • Small hydrophobic (SH) protein: blocks TNFα-mediated apoptosis
  • Non-structural proteins NS1 and NS2 (V proteins): inhibit IFN production and signaling
  • Haemagglutinin-neuraminidase (HN) glycoprotein: binds with extracellular host cell sialic acid

Resources

References

  1. Rubin S, Eckhaus M, Rennick LJ, Bamford CG, Duprex WP (2015). "Molecular biology, pathogenesis and pathology of mumps virus". J Pathol. 235 (2): 242–52. doi:10.1002/path.4445. PMC 4268314. PMID 25229387.
  2. He B, Lin GY, Durbin JE, Durbin RK, Lamb RA (2001). "The SH integral membrane protein of the paramyxovirus simian virus 5 is required to block apoptosis in MDBK cells". J Virol. 75 (9): 4068–79. doi:10.1128/JVI.75.9.4068-4079.2001. PMC 114152. PMID 11287556.
  3. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S; et al. (2004). "The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter". Proc Natl Acad Sci U S A. 101 (49): 17264–9. doi:10.1073/pnas.0407639101. PMC 535396. PMID 15563593.


Template:WikiDoc Sources